Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research

Published: Tuesday, September 30, 2008
Last Updated: Tuesday, September 30, 2008
Bookmark and Share
EPI will employ its tissue proteomics technologies to identify protein biomarkers of metastasis.

Expression Pathology Inc. (EPI) will collaborate with the Alberta Cancer Board, Tom Baker Cancer Centre (Calgary, Alberta) to identify protein biomarkers of breast cancer metastasis. The project is funded by a $300,000 CAD grant from the Alberta Cancer Board and Foundation, a leading funding body for collaborative cancer research in Alberta.

EPI will employ its proprietary tissue proteomics technologies to study archived formalin-fixed breast cancer tissue samples from patients treated at the Tom Baker Cancer Centre. EPI’s Liquid Tissue® sample preparation and Director™ laser microdissection will enable in-depth mass spectrometry analysis of tissue samples that have detailed pathology and clinical outcome data.

Over 200,000 cases of early-stage breast cancer present for treatment decisions each year in North America. Proteins make up the molecular pathways which control cell functions and are the targets of drug action. This protein-based approach may yield valuable tissue biomarkers of breast cancer metastasis as well as potential new cancer drug targets.

“Assessment of the state of metastasis of breast cancer patients is key to optimal treatment decisions,” says Dr. Anthony Magliocco, Director of Pathology at the Tom Baker Cancer Centre and Associate Professor of Oncology, Pathology and Laboratory Medicine at the University of Calgary. “Our project with EPI will strive to identify proteins in primary tumor tissue that may serve as biomarkers of the early stages of metastasis at the molecular level.”

“This project is exactly how we see our proprietary tissue proteomics research platform being used, to understand at the protein level the progression of metastasis in early-stage breast cancer,” says Casimir Eitner, EPI’s President and CEO.

“Our aim is to develop valuable tissue protein assays that can aid patient treatment decisions and to identify new therapeutic targets and companion diagnostics to those targets. We greatly appreciate the Alberta Cancer Board’s support of this innovative initiative and recognition of the value of our company’s technology,” Eitner says.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Expression Pathology Obtains Second U.S. Liquid Tissue® Patent
Patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company’s patented Liquid Tissue® method.
Sunday, April 10, 2011
Expression Pathology Provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
The Liquid Tissue®-SRM Technology accelerates identification of cancer molecular markers for developing more effective treatments.
Wednesday, January 12, 2011
Expression Pathology provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
Expression Pathology Inc. announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.
Tuesday, January 11, 2011
Flagship Partners with Expression Pathology to Combine Tissue Proteomics and Digital Pathology
Two leading companies offer clients integrated services for digital pathology and quantitative mass-spec based tissue proteomics.
Sunday, December 12, 2010
Expression Pathology’s Liquid Tissue Patent Issues in Japan
Patent covers tissue processing methods to enable discovery and accurate measurement of protein biomarkers in standard FFPE tissue by mass spectrometry.
Tuesday, September 28, 2010
Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology
The patent claims methods to enable protein analysis in FFPE tissue for clinical research and diagnostics.
Wednesday, January 07, 2009
EPI Licenses Harvard’s AQUA™ Peptide Technology
Company licenses the patent rights for mass spectrometry quantitation of proteins in patient tissue.
Wednesday, August 30, 2006
Publication Shows Cancer Biomarker Identification in Formalin-Fixed Tissue
The article describes LC MS/MS mass spectrometry analysis of FFPE prostate cancer tissue.
Thursday, November 10, 2005
Scientific News
Metabolite Promotes Cancer Cell Transformation
Researchers have identified a metabolite that promotes cancer cell transformation and colorectal cancer spread.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Hunting the Missing Link Between Genetics and the Environment
The International Phenome Centre Network (IPCN) works to transform healthcare through phenomics - the dynamic interactions between our genes and our environment.
Cocaine Test Could Lead to Rapid, Low Cost Roadside Testing
Scientists develop urine and oral fluid diagnostic test for cocaine, utilising a compact mass spectrometer.
The Benefits of a Mediterranean-style Diet
A Western-style diet, with more omega-6 fatty acids than the Mediterranean, dysregulates lipid signaling in aged mice and promotes inflammation.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Rapid Identification of Illicit Designer Drugs
New technique can identify commonly used illicit compounds in as little as 15 seconds.
Enhancing On-line Biological Sample Processing
New techniques are required to meet emerging demands on biopharmaceutical analysis.
Early Warning System for Colorectal Cancer
Potential new diagnostic tool identified for the second most common cancer in the world.
Scientists Develop a Novel Method to Benchmark and Improve the Performance of Protein Measurement Techniques
A wide range of laboratories around the world are benefiting from this work, which enables researchers to analyze or compare the results of quantitative proteomics assays in a standardized way.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!